TITLE:
An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)

CONDITION:
Lung Disease

INTERVENTION:
interferon-gamma 1b

SUMMARY:

      Study GIPF-004 is an open-label, multicenter study that will enroll approximately 250
      patients who complete Protocol GIPF-001. The purpose of this study is to assess the safety
      and efficacy of continued IFN-gamma 1b therapy in this well-defined cohort of patients for
      up to 48 weeks.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 20 Years to 79 Years
Criteria:

        Male or Female

        Idiopathic Pulmonary Fibrosis

        20-79 years

        Must have participated in the InterMune protocol GIPF-001 study.
      
